Sitagliptin (100 mg/day) was administrated for 4 weeks
Significant improvement in myocardial function and reduction in postischemic stunning (ejection fraction, 70.5 ± 7.0 versus 65.7 ± 8.0%; ; strain rate in ischemic segments, −2.27 ± 0.65 versus −1.988 ± 0.58 s−1; )
Sitagliptin 100 mg/day (or 50 mg/day if the baseline GFR was ≥30 and <50 mL per minute per 1.73 m2) Median follow-up was 3.0 years
Sitagliptin was noninferior to placebo for the primary compositive cardiovascular outcome (hazard ratio, 0.98; 95% CI, 0.88 to 1.09; ). Rates of hospitalization for heart failure did not differ between the two groups (hazard ratio, 1.00; 95% CI, 0.83 to 1.20; )
Pfeffer et al. (presentation abstract; American Diabetes Association 75th Scientific Sessions, 2015 Lixisenatide (ELIXA); 2015)
Lixisenatide, 3034; placebo, 3034
Lixisenatide 10–20 g/day Median follow-up was 2.1 years
Lixisenatide was noninferior to placebo for the primary compositive cardiovascular outcome (hazard ratio, 0.97; 95% CI, 0.85 to 1.10). Rates of hospitalization for heart failure did not differ between the two groups (hazard ratio, 0.94; 95% CI, 0.78 to 1.13). Rates of mortality (hazard ratio, 0.94; 95% CI, 0.78 to 1.13)
Hybrid (landrace and large white) pigs with BNP infusion + sitagliptin; 6 Placebo; 6
Sitagliptin (30 mg/kg/BW) was orally administrated for 3 weeks
An increase in stroke volume was observed in the sitagliptin group compared with placebo (+24 + 6% versus −17 + 7%, ). Glomerular filtration rate declined at week 4 compared with baseline in the placebo group (1.3 + 0.4 versus 2.3 + 0.3 mL/kg/min, )